PLx Pharma Inc. (NASDAQ:PLXP) Q3 2019 Earnings Conference Call - Final Transcript
Nov 08, 2019 • 08:30 am ET
Ladies and gentlemen, thank you for standing by and welcome to the PLx Pharma Q3 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]
I would now like to hand the conference over to your speaker today, Lisa Wilson, Investor Relations of PLx Pharma. Please go ahead ma'am.
Thank you, Josh. Welcome to PLx Pharma's Q3 2019 Earnings Results Call. This is Lisa Wilson of In-Site Communications, Investor Relations for PLx. With me on today's call are Natasha Giordano, President and Chief Executive Officer; and Rita O'Connor, Chief Financial Officer of PLx. You can also access the webcast of this call through the Investors section of the PLx website at plxpharma.com.
Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation or intent regarding future events and the Company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to PLx Pharma's management as of today and involve risks and uncertainties including those noted in our press release issued this morning and our filings with the SEC. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. PLx specifically disclaims any intent or obligation to update these forward-looking statements except as required by law.
The archived webcast will be available for 30 days on our website, plxpharma.com. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on November 8, 2019. Since then, PLx may have made announcements related to the topics discussed, so please reference the Company's most recent press releases and SEC filings.
And with that, I'll turn the call over to PLx's CEO, Natasha Giordano.
Thank you, Lisa. Good morning everyone, and thank you for joining our call. This is an especially exciting time for us at PLx as we approach the final phases of the regulatory process for VAZALORE and make progress toward our planned launch in the middle of next year. We are tracking well against our milestones as I'll share in a few moments and we are particularly encouraged by the growing enthusiasm for our innovative products, both within the clinical community and from the retail trade. We're engaged in typical interactions with the FDA to clarify labeling and data requirements for our supplemental new drug application submission.
In the time leading up to our commercial launch, we're implementing our publication strategy to raise awareness in the medical community with data supporting the efficacy and safety of VAZALORE. There's a great deal of interest in aspirin therapy today, and we believe the market is ready for a novel therapeutic agent that provides faster, more reliable